Hereditary angioedema (hae) Trials in Hershey, United States
Conditions / Hereditary angioedema (hae) / Hershey, United States
Hereditary angioedema (hae) is a medical condition with active clinical research programs worldwide.
13 total trials for this combination
Showing top 10 of 13 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07428499 | Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) | RECRUITING | — |
| NCT01386658 | A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema | COMPLETED | PHASE3 |
| NCT02093923 | A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants | COMPLETED | PHASE1 |
| NCT05396105 | Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | ENROLLING_BY_INVITATION | PHASE2/PHASE3 |
| NCT02586805 | Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE | COMPLETED | PHASE3 |
| NCT00457015 | Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE) | COMPLETED | PHASE3 |
| NCT01059526 | Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema | COMPLETED | — |
| NCT02741596 | Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE | COMPLETED | PHASE3 |
| NCT00456508 | Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) | COMPLETED | PHASE3 |
| NCT03845400 | A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America | COMPLETED | — |